ArticleTherapeutic innovation & regulatory science2026
Two Decades of Progress and Remaining Challenges: Comparative Analysis of Rare Disease Policy Implementation in Bulgaria, Romania, and Greece.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRare diseases (RDs) pose significant challenges to public health, affecting millions of individuals across the world. Since the adoption of Regulation (EC) No. 141/2000, the European Union (EU) has provided a unified framework for national RD policies. This study provides an overview of RDs legislation over the past two decades (2000-2024), with a comparative analysis of the period 2012-2024 in three neighbouring EU Member States: Bulgaria, Romania, and Greece. The analysis focuses on legal frameworks, national strategies, centres of expertise (CEs), and disease registries.
resultsAll three countries have developed RD-related policy structures aligned with EU standards; however, important differences remain in their level of institutionalisation, coordination, and implementation. Bulgaria demonstrates a more formalised organisational framework through the early adoption of a dedicated National Rare Disease Programme (NRDP), an official RD list, and formal coordination mechanisms, alongside the expansion of CEs, disease registries, and neonatal screening. In contrast, Romania and Greece lack updated standalone NRDPs, with Romania integrating RD policies within broader national health strategies and Greece relying more on fragmented initiatives and broader healthcare reforms. While CEs, registries, and neonatal screening programmes are present across all three countries, differences persist in their organisation, national coordination, and degree of integration. Overall, the existence of policy frameworks and organisational structures does not necessarily indicate their effective implementation, integration, or equitable patient access.
conclusionsRD policy frameworks in Bulgaria, Romania, and Greece have developed over the past two decades, reflecting progressive alignment with EU-level recommendations. However, implementation remains uneven, fragmented, and differently organised across the three countries. These findings suggest that legislative harmonisation alone is insufficient to ensure coordinated and effective RD policy implementation. Future research is needed to examine how these structures function in practice and whether they improve healthcare delivery, care coordination, and patient outcomes.
Indexed as
Identifiers
42436312What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.